AIM VACCINE's serum-free iterative rabies vaccine has been accepted for market registration.

The group has announced that the serum-free iterative rabies vaccine developed by the group has been registered by the National Medical Products Administration, with acceptance number CXSS2500044. In addition, the group's wholly-owned subsidiary, Aimei Rongyu (Ningbo) Biopharmaceutical Co., Ltd., recently obtained the corresponding product production license for the serum-free iterative rabies vaccine. Currently, there is no serum-free rabies vaccine approved for marketing on the global market. This product is expected to become the first product on the market, marking a major technological breakthrough for the group and further strengthening its global leading position in the field of rabies vaccines. Rabies is the deadliest disease in the world, with a mortality rate close to 100% after onset. Currently, there is a lack of effective treatment methods for rabies in clinical practice, so prevention after exposure is crucial. The main preventive measure is the vaccination of human rabies vaccine. There are two types of rabies vaccines, one is a serum rabies vaccine, and the other is a serum-free rabies vaccine, but currently there are no serum-free rabies vaccines registered for marketing globally. The mainstream Vero cell rabies vaccine and human diploid cell rabies vaccine on the market are both serum rabies vaccines. Compared to traditional Vero cell rabies vaccines and human diploid cell rabies vaccines, the serum-free iterative rabies vaccine developed by the group is completely different, as it is an iteratively upgraded product. Residual animal serum in vaccine products is one of the important factors leading to allergic reactions and other adverse reactions in the vaccinated population. The serum-free iterative rabies vaccine developed by the group does not contain animal serum, significantly improving safety and reducing the probability of adverse reactions. China is the world's largest rabies vaccine market, and according to Zhoushi Consulting statistics, driven by product updates and iterations and increased prevalence of rabies vaccines, it is expected to reach RMB 14.8 billion by 2030. According to the "Rabies Exposure Prevention and Control Work Standards (2023 Edition)" formulated by the National Health Commission and the National Health Commission, outpatient vaccinations with rabies vaccine must be equipped with at least two different types of rabies vaccines, and the group's products with its iterative technological advantages are expected to become preferred by vaccine vaccination institutions. As the world's second largest rabies vaccine supplier, the group is committed to leading the deep technological iteration and upgrading of global rabies vaccines. It has completed the construction of a serum-free iterative rabies vaccine workshop that meets international standards, and has completed commercial-scale verification production. It has the capacity for large-scale production of this product, and once the product is approved, it can be quickly launched into the market. In the future, the approval of this vaccine for marketing and sales is expected to significantly boost the group's performance.